These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 21915635)

  • 21. The predictive and therapeutic value of thymidine phosphorylase and dihydropyrimidine dehydrogenase in capecitabine (Xeloda)-based chemotherapy for head and neck cancer.
    Saito K; Khan K; Yu SZ; Ronson S; Rhee J; Li G; Van Echo D; Suntharalingam M; O'Malley BW; Li D
    Laryngoscope; 2009 Jan; 119(1):82-8. PubMed ID: 19117293
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of introduction of dThdPase cDNA on sensitivity to 5'-deoxy-5-fluorouridine and tumor angiogenesis.
    Kim R; Murakami S; Toge T
    Int J Oncol; 2003 Apr; 22(4):835-41. PubMed ID: 12632076
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bioactivation of capecitabine in human liver: involvement of the cytosolic enzyme on 5'-deoxy-5-fluorocytidine formation.
    Tabata T; Katoh M; Tokudome S; Hosakawa M; Chiba K; Nakajima M; Yokoi T
    Drug Metab Dispos; 2004 Jul; 32(7):762-7. PubMed ID: 15205393
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Enhanced anticancer effects of 5'-DFUR on colorectal cancer cell lines SW480 and LOVO by transfection with thymidine phosphorylase cDNA].
    Liu J; Zhang JM; Gao Q; Wang QW; Ye DJ; Liu Y
    Zhonghua Wai Ke Za Zhi; 2013 Jul; 51(7):636-40. PubMed ID: 24256592
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative antitumor activity of 5-fluorouracil and 5'-deoxy-5-fluorouridine in combination with interferon gamma in renal cell carcinoma cell lines.
    Ikemoto S; Sugimura K; Yoshida N; Kuratsukuri K; Wada S; Nakatani T
    Anticancer Res; 2002; 22(6C):4023-7. PubMed ID: 12553027
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preferential inhibition of bone metastases by 5'-deoxy-5-fluorouridine and capecitabine in the 4T1/luc mouse breast cancer model.
    Hiraga T; Hata K; Ikeda F; Kitagaki J; Fujimoto-Ouchi K; Tanaka Y; Yoneda T
    Oncol Rep; 2005 Sep; 14(3):695-9. PubMed ID: 16077977
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Effect of thymidine phosphorylase cDNA transfection on the inhibition of human colon carcinoma cell line by 5'-deoxy-5-fluorouridine].
    Gao Q; Zhang JM; Liu J; Wang QW; Ye DJ; Liu Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Apr; 16(4):370-5. PubMed ID: 23608802
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetic and pharmacodynamic comparison of fluoropyrimidine derivatives, capecitabine and 5'-deoxy-5-fluorouridine (5'-DFUR).
    Ebi H; Sigeoka Y; Saeki T; Kawada K; Igarashi T; Usubuchi N; Ueda R; Sasaki Y; Minami H
    Cancer Chemother Pharmacol; 2005 Aug; 56(2):205-11. PubMed ID: 15844007
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5'-deoxy-5-fluorouridine by cyclophosphamide in mammary tumor models.
    Endo M; Shinbori N; Fukase Y; Sawada N; Ishikawa T; Ishitsuka H; Tanaka Y
    Int J Cancer; 1999 Sep; 83(1):127-34. PubMed ID: 10449619
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Pharmacological and clinical properties of Xeloda (Capecitabine), a new oral active derivative of fluoropyrimidine].
    Nishida M
    Nihon Yakurigaku Zasshi; 2003 Dec; 122(6):549-53. PubMed ID: 14639009
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical efficacy of doxifluridine and correlation to in vitro sensitivity of anticancer drugs in patients with colorectal cancer.
    Yamaue H; Tanimura H; Kono N; Aoki Y; Tabuse K; Uchiyama K; Takifuji K; Iwahashi M; Tani M
    Anticancer Res; 2003; 23(3B):2559-64. PubMed ID: 12894541
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increased sensitivity to the prodrug 5'-deoxy-5-fluorouridine and modulation of 5-fluoro-2'-deoxyuridine sensitivity in MCF-7 cells transfected with thymidine phosphorylase.
    Patterson AV; Zhang H; Moghaddam A; Bicknell R; Talbot DC; Stratford IJ; Harris AL
    Br J Cancer; 1995 Sep; 72(3):669-75. PubMed ID: 7669579
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antitumor activity of combination treatment with gefitinib and docetaxel in EGFR-TKI-sensitive, primary resistant and acquired resistant human non-small cell lung cancer cells.
    Wu M; Yuan Y; Pan YY; Zhang Y
    Mol Med Rep; 2014 Jun; 9(6):2417-22. PubMed ID: 24682085
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antitumor activity of chemoendocrine therapy in premenopausal and postmenopausal models with human breast cancer xenografts.
    Kataoka M; Yamaguchi Y; Moriya Y; Sawada N; Yasuno H; Kondoh K; Evans DB; Mori K; Hayashi S
    Oncol Rep; 2012 Feb; 27(2):303-10. PubMed ID: 22076074
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Influence of interferon-α2a on thymidine phosphorylase expression and anticancer activity of 5'-deoxy-fluorouridine in human colon carcinoma cell lines LOVO and SW480].
    Xia Q; Wang QW; Zhang JM
    Zhonghua Wei Chang Wai Ke Za Zhi; 2012 Jul; 15(7):719-22. PubMed ID: 22851078
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Histone deacetylase inhibitors induce thymidine phosphorylase expression in cultured breast cancer cell lines.
    Puppin C; Puglisi F; Pandolfi M; Di Loreto C; Damante G
    Oncol Rep; 2011 Aug; 26(2):309-14. PubMed ID: 21617864
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer and normal mucosa in patients.
    Amatori F; Di Paolo A; Del Tacca M; Fontanini G; Vannozzi F; Boldrini L; Bocci G; Lastella M; Danesi R
    Pharmacogenet Genomics; 2006 Nov; 16(11):809-16. PubMed ID: 17047489
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of potentially useful combinations of epidermal growth factor receptor tyrosine kinase antagonists with conventional cytotoxic agents using median effect analysis.
    Budman DR; Soong R; Calabro A; Tai J; Diasio R
    Anticancer Drugs; 2006 Sep; 17(8):921-8. PubMed ID: 16940802
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of the human concentrative nucleoside transporter (hCNT1) in the cytotoxic action of 5[Prime]-deoxy-5-fluorouridine, an active intermediate metabolite of capecitabine, a novel oral anticancer drug.
    Mata JF; García-Manteiga JM; Lostao MP; Fernández-Veledo S; Guillén-Gómez E; Larrayoz IM; Lloberas J; Casado FJ; Pastor-Anglada M
    Mol Pharmacol; 2001 Jun; 59(6):1542-8. PubMed ID: 11353816
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients.
    Poole C; Gardiner J; Twelves C; Johnston P; Harper P; Cassidy J; Monkhouse J; Banken L; Weidekamm E; Reigner B
    Cancer Chemother Pharmacol; 2002 Mar; 49(3):225-34. PubMed ID: 11935215
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.